

SEQUENCE LISTING

<110> Ledbetter, Jeffrey

Hayden-Ledbetter, Martha

<120> Binding Domain-Immunoglobulin Fusion Proteins

<130> 390069.401

<140> US

<141> 2002-01-17

<150> US 09/765,208

<151> 2001-01-17

<160> 38

<170> PatentIn version 3.0

<210> 1

<211> 812

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE SCFV FUSION GENE

<220>

<221> sig_peptide

<222> (13)..(78)

<220>

<221> V_region

<222> (79)..(396)

<223> light chain variable region for anti-CD20 scFv

<220>

<221> misc_feature

<222> (397)..(444)

<223> asp-gly3ser(gly4ser)2-ser peptide linker

<220>

<221> V_region

<222> (445)..(808)

<223> heavy chain variable region for anti-CD20 scFv

<400> 1

```

aagcttgccg ccatggattt tcaagtgcag attttcagct tcttgcta at cagtgttca      60
gtcataattg ccagaggaca aattgttctc tcccagtctc cagcaatcct gtctgcatct      120
ccaggggaga aggtcacaaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg      180
taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc caacctgggt      240
tctggagtcc ctgtctgctt cagtggcagt ggggtctggga cctcttactc tctcacaatc      300
agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag ttttaacca      360
cccacgttcg gtgtgtgggac caagctggag ctgaaagggt gcggtggctc gggcggtgggt      420
ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctgggt      480
aggcctgggg cctcagtgaat gatgtcctgc aaggcttctg gctacacatt taccagttac      540
aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat      600
ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta      660
gacaaatcct ccagcacagc ctacatgcag ctacagcagc tgacatctga agactctgcg      720
gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg      780

```

ggcacagggga ccacgggtcac cgtctctgat ca

812

<210> 2

<211> 1518

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE HUMAN CHIMERIC FUSION GENE

<220>

<221> misc_feature

<222> (13)..(807)

<223> MURINE ANTI-HUMAN CD20 scFv

<220>

<221> C_region

<222> (808)..(1513)

<223> HUMAN IgG1 Fc TAIL, WILD TYPE HINGE, CH2 AND CH3

<400> 2

aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaata cagtgccttca 60

gtcataaattg ccagaggaca aattgtttctc tcccagttctc cagcaatcct gtctgcatct 120

ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180

taccagcaga agccaggatc ctcccccaaa ccttggattt atgccccatc caacctgggt 240

tctggagtcc ctgctcgctt cagtggcagt ggggtctggga cctcttactc tctcacaatc 300

agcagagtgg aggtgaaga tgctgccact tattactgcc agcagtggag ttttaaccca 360

cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcgggtgg 420

ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctgggt 480

aggcctgggg cctcagtga gatgtcctgc aaggcttctg gctacacatt taccagttac 540

aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat 600

```

ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta 660
gacaaatcct ccagcacagc ctacatgcag ctccagcagc tgacatctga agactctgcg 720
gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg 780
ggcacaggga ccacggtcac cgtctctgat caggagccca aatcttgtga caaaactcac 840
acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc 900
ccaaaaccca aggacaccct catgatctcc cggacccttg aggtcacatg cgtggtggtg 960
gacgtgagcc acgaagaccc tgagggtcaag ttcaactggt acgtggacgg cgtggaggtg 1020
cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc 1080
gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggctctcc 1140
aacaaagccc tcccagcccc catcgagaaa acaatctcca aagccaaagg gcagccccga 1200
gaaccacagg tgtacaccct gccccatcc cgggatgagc tgaccaagaa ccaggtcagc 1260
ctgacctgcc tgggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 1320
gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc 1380
ttcctctaca gcaagctcac cgtggacaag agcagggtggc agcaggggaa cgtcttctca 1440
tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct 1500
ccgggtaaat gatctaga 1518

```

<210> 3

<211> 1518

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE-HUMAN CHIMERIC FUSION GENE

<220>

<221> misc_feature

<222> (13)..(807)<223> MOUSE ANTI-HUMAN CD20 SCFV

<220>

<221> C_region

<222> (808)..(1513)

<223> HINGE CYSTEINES (826-829; 844-847; 853-856) MUTATED TO SERINES
PROLINE TO SERINE MUTATION (880-883) IN CH2 DISRUPTS EFFECTOR FUNCTION

<400> 3

```

aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaata cagtgccttca      60
gtcataattg ccagaggaca aattgttctc tcccagctctc cagcaatcct gtctgcatct      120
ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagta catgcactgg      180
taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc caacctgggt      240
tctggagtcc ctgctcgctt cagtggcagt ggggtctggga cctcttactc tctcacaatc      300
agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca      360
cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcgggtgg      420
ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctgggtg      480
aggcctgggg cctcagtgaag gatgtcctgc aaggcttctg gctacacatt taccagttac      540
aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatattat      600
ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta      660
gacaaaatcct ccagcacagc ctacatgcag ctacagcagc tgacatctga agactctgcg      720
gtctatatttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg      780
ggcacagggg ccacggtcac cgtctctgat caggagccca aatcttctga caaactcac      840
acatccccac cgtccccagc acctgaactc ctggggggat cgtcagtctt cctcttcccc      900
ccaaaaccca aggacaccct catgatctcc cggacccttg aggtcacatg cgtggtggtg      960
gacgtgagcc acgaagaccc tgagggtcaag ttcaactggg acgtggacgg cgtggaggtg     1020
cataatgccg agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc     1080
gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggtctcc     1140
aaciaaagccc tcccagcccc catcgagaaa acaatctcca aagccaaagg gcagccccga     1200
gaaccacagg tgtacaccct gccccatcc cgggatgagc tgaccaagaa ccaggtcagc     1260
ctgacctgcc tgggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat     1320
gggcagccgg agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc     1380

```

```

ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 1440
tgctccgtga tgcatgaggc tctgcacaac cactacacgc agaagagcct ctccctgtct 1500
ccgggtaaat gatctaga 1518

```

<210> 4

<211> 1518

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE-HUMAN CHIMERIC FUSION GENE

<220>

<221> misc_feature

<222> (13)..(807)

<223> MOUSE ANTI-HUMAN CD20 SCFV

<220>

<221> C_region

<222> (808)..(1513)

<223> HINGE CYSTEINES MUTATED TO SERINES (826-829; 844-847; 853-856)
WILD TYPE CH2 AND CH3 DOMAINS MEDIATE EFFECTOR FUNCTIONS

<400> 4

```

aagcttgccg ccatggattt tcaagtgcag attttcagct tcttgctaatt cagtgtttca 60
gtcataattg ccagaggaca aattgtttctc tcccagtctc cagcaatcct gtctgcatct 120
ccaggggaga aggtcacaat gacttgacagg gccagctcaa gtgtaagtta catgcactgg 180
taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc caacctgggt 240
tctggagtcc ctgctcgctt cagtggcagt ggggtctggga cctcttactc tctcacaatc 300
agcagagtgg aggctgaaga tgctgccact tattactgcc agcagtggag ttttaaccac 360
cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcggtggt 420

```

```

ggatctggag gagtgaggag ctctcaggct tatctacagc agtctggggc tgagctggtg 480
aggcctgggg cctcagtga gatgtcctgc aaggcttctg gctacacatt taccagttac 540
aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat 600
ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta 660
gacaaatcct ccagcacagc ctacatgcag ctcagcagcc tgacatctga agactctgcg 720
gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg 780
ggcacagggg ccacggtcac cgtctctgat caggagccca aatcttctga caaaactcac 840
acatccccac cgtccccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc 900
ccaaaacca aggacaccct catgatctcc cggaccctg aggtcacatg cgtggtggtg 960
gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt acgtggacgg cgtggaggtg 1020
cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc 1080
gtcctcaccg tcctgcacca ggactggctg aatggcaagg agtacaagtg caaggctctcc 1140
aaciaagccc tcccagcccc catcgagaaa acaatctcca aagccaaagg gcagccccga 1200
gaaccacagg tgtacacct gcccccattc cgggatgagc tgaccaagaa ccaggtcagc 1260
ctgacctgcc tgggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat 1320
gggcagccgg agaacaacta caagaccacg cctcccgctg tggactccga cggctccttc 1380
ttcctctaca gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca 1440
tgctccgtga tgcatgaggc totgcacaac cactacagc agaagagcct ctccctgtct 1500
ccgggtaaat gatctaga 1518

```

<210> 5

<211> 1524

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE HUMAN CHIMERIC FUSION GENE

<220>

<221> misc_feature

<222> (1)..(796)

<223> MOUSE ANTI HUMAN CD20 SCFV

<220>

<221> N_region

<222> (797)..(864)

<223> HUMAN IGA HINGE REGION

<220>

<221> C_region

<222> (865)..(1518)

<223> HUMAN IGG1 CH2 AND CH3 WILD TYPE FC DOMAIN

<400> 5

```

atggattttc aagtgcagat tttcagcttc ctgctaataca gtgcttcagt cataattgcc      60
agaggacaaa ttgttctctc ccagtctcca gcaatcctgt ctgcatctcc aggggagaag      120
gtcacaaatga cttgcagggc cagctcaagt gtaagttaca tgcactggta ccagcagaag      180
ccaggatcct cccccaacc ctggatttat gccccatcca acctggcttc tggagtcctt      240
gctcgcttca gtggcagtggt gtctgggacc tcttactctc tcacaatcag cagagtggag      300
gctgaagatg ctgccactta ttactgccag cagtggagtt ttaaccacc caggttcggt      360
gctgggacca agctggagct gaaagatggc ggtggctcgg gcggtggtgg atctggagga      420
ggtgggagct ctcaggctta ttacagcag tctggggctg agctggtgag gcctggggcc      480
tcagtgaaga tgcctgcaa ggcttctggc tacacattta ccagttacaa tatgcactgg      540
gtaaagcaga cacctagaca gggcctggaa tggattggag ctatttatcc aggaaatggt      600
gatacttcct acaatcagaa gttcaagggc aaggccacac tgactgtaga caaatcctcc      660
agcacagcct acatgcagct cagcagcctg acatctgaag actctgcggt ctatttctgt      720
gcaagagtgg tgtactatag taactcttac tgggtacttcg atgtctgggg cacagggacc      780
acggtcaccg tctctgatca gccagttccc tcaactccac ctaccccatc tccctcaact      840
ccacctaccc catctccctc atgcgcacct gaactcctgg ggggaccgtc agtcttcctc      900

```



```

ttccccccaa aacccaagga caccctcatg atctcccga cccctgaggt cacatgcgtg 960
gtggtgggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg 1020
gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg 1080
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag 1140
gtctccaaca aagccctccc agcccccatc gagaaaacaa tctccaaagc caaagggcag 1200
ccccgagaac cacaggtgta caccctgccc ccatcccggg atgagctgac caagaaccag 1260
gtcagcctga cctgcctggg caaaggcttc tatcccagcg acatcgccgt ggagtgggag 1320
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1380
tccttcttcc tctacagcaa gctcaccgtg gacaagagca ggtggcagca ggggaacgtc 1440
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacgcagaa gagcctctcc 1500
ctgtctccgg gtaaattgatc taga 1524

```

<210> 6

<211> 711

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC HUMAN PARTIAL FUSION GENE

<220>

<221> misc_feature

<222> (1)..(705)

<223> HINGE CYSTEINES MUTATED TO SERINES (19-21; 37-39; 46-48)

```

<400> 6
gatcaggagc ccaaattctt tgacaaaact cacacatccc caccgtcccc agcacctgaa 60
ctcctggggg gaccgtcagt ctctctcttc cccccaaaac ccaaggacac cctcatgac 120
tccgggaccc ctgaggtcac atgcgtgggt gtggacgtga gccacgaaga ccctgaggtc 180
aagttcaact ggtacgtgga cggcgtggag gtgcataatg ccaagacaaa gccgcgggag 240
gagcagtaca acagcacgta ccgtgtgggt agcgtcctca ccgtcctgca ccaggactgg 300

```

```

ctgaatggca aggagtacaa gtgcaaggtc tccaacaaag ccctcccagc ccccatcgag 360
aaaacaatct ccaaagccaa agggcagccc cgagaaccac aggtgtacac cctgccccca 420
tcccgggatg agctgaccaa gaaccaggtc agcctgacct gcctgggtcaa aggccttctat 480
cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa ctacaagacc 540
acgcctcccg tgctggactc cgacggctcc ttcttcctct acagcaagct caccgtggac 600
aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga ggctctgcac 660
aaccactaca cgcagaagag cctctccctg tctccgggta aatgatctag a 711

```

<210> 7

<211> 729

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC HUMAN PARTIAL FUSION GENE

<220>

<221> N_region

<222> (1)..(69)

<223> HUMAN IGA HINGE

<220>

<221> C_region

<222> (70)..(723)

<223> HUMAN WILD TYPE IGG1 CH2 AND CH3, FC

<400> 7

```

gatcagccag ttccctcaac tccacctacc ccctctccct caactccacc taccatctct 60
ccctcatgcy cacctgaact cctgggggga cgtcagttct tcctcttccc cccaaaaccc 120
aaggacaccc tcatgatctc ccggaccctt gaggtcacat gcgtgggtgt ggacgtgagc 180
cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 240

```

```

aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtgggtcag cgtcctcacc      300
gtcctgcacc aggactggct gaatggcaag gagtacaagt gcaagggtctc caacaaagcc      360
ctcccagccc ccatcgagaa aacaatctcc aaagccaaag ggcagccccg agaaccacag      420
gtgtacaccc tgcccccatc ccgggatgag ctgaccaaga accagggtcag cctgacctgc      480
ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg      540
gagaacaact acaagaccac gctcccgtg ctggactccg acggctcctt cttcctctac      600
agcaagctca ccgtaggaaa gagcaggtgg cagcagggga acgtcttctc atgctccgtg      660
atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc tccgggtaaa      720
tgatctaga                                     729

```

<210> 8

<211> 825

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE SCFV FUSION GENE

<220>

<221> misc_feature

<222> (13)..(72)

<223> LIGHT CHAIN LEADER PEPTIDE

<220>

<221> V_region

<222> (73)..(405)

<223> LIGHT CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD19: HD37

<220>

<221> misc_feature

<222> (406)..(450)

<223> SYNTHETIC (GLY4SER)3 LINKER PEPTIDE

<220>

<221> V_region

<222> (454)..(825)

<223> HEAVY CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD19: HD37

<400> 8

```

aagcttgccg ccatggagac agacacactc ctgctatggg tgctgctgct ctgggttcca      60
ggctccactg gtgacattgt gctgacccaa tctccagctt ctttggctgt gtctctaggg      120
cagagggcca ccatctcctg caaggccagc caaagtgttg attatgatgg tgatagttat      180
ttgaactggt accaacagat tccaggacag ccacccaaac tcctcatcta tgatgcatcc      240
aatctagttt ctgggatccc acccaggttt agtggcagtg ggtctgggac agacttcacc      300
ctcaacatcc atcctgtgga gaagggtgat gctgcaacct atcactgtca gcaaagtact      360
gaggatccgt ggacgttcgg tggaggcacc aagctggaaa tcaaagggtg cggtgggctcg      420
ggcggtggtg ggtcgggtgg cggcgggatcg tcacaggttc agctgcagca gtctggggct      480
gagctggtga ggcctgggtc ctcaagtgaag atttctctgca aggcttctgg ctatgcattc      540
agtagctact ggatgaactg ggtgaagcag aggcctggac agggctcttga gtggattgga      600
cagatttggtc ctggagatgg tgatactaac tacaatggaa agttcaaggg taaagccact      660
ctgactgcag acgaatcctc cagcacagcc tacatgcaac tcagcagcct agcatctgag      720
gactctgcgg tctatttctg tgcaagacgg gagactacga cggtaggccg ttattactat      780
gctatggact actgggggtca aggaacctca gtcaccgtct cctca                      825

```

<210> 9

<211> 795

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE SCFV FUSION GENE

<220>

<221> misc_feature

<222> (13)..(72)

<223> LIGHT CHAIN LEADER PEPTIDE SEQUENCE

<220>

<221> V_region

<222> (73)..(393)

<223> LIGHT CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD37: G28-1

<220>

<221> misc_feature

<222> (394)..(441)

<223> SYNTHETIC LINKER PEPTIDE ENCODED (GLY4SER)3

<220>

<221> V_region

<222> (442)..(795)

<223> HEAVY CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD37: G28-1

<400> 9

aagcttgccg ccatggtatc cacagctcag ttccttgggt tgctgctgct gtggcttaca	60
ggtggcagat gtgacatcca gatgactcag tctccagcct ccctatctgc atctgtggga	120
gagactgtca ccatcacatg tcgaacaagt gaaaatgttt acagttatTT ggcttggtat	180
cagcagaaac agggaaaatc tcctcagctc ctggtctctt ttgcaaaaac cttagcagaa	240
ggtgtgccat caaggttcag tggcagtgga tcaggcacac agttttctct gaagatcagc	300
agcctgcagc ctgaagattc tggaagttat ttctgtcaac atcattccga taatccgtgg	360
acgttcggtg gaggcaccga actggagatc aaaggtggcg gtggctcggg cggtgggtggg	420
tcgggtggcg gcggatcgtc agcgggtccag ctgcagcagt ctggacctga gctggaaaag	480

```

cctggcgctt cagtgaagat ttcctgcaag gcttctggtt actcattcac tggctacaat 540
atgaactggg tgaagcagaa taatggaaag agccttgagt ggattggaaa tattgatcct 600
tattatgggtg gtactaccta caaccggaag ttcaagggca aggccacatt gactgtagac 660
aaatcctcca gcacagccta catgcagctc aagagtctga catctgagga ctctgcagtc 720
tattactgtg caagatcggg cggccctatg gactactggg gtcaaggaac ctcagtcacc 780
gtctcttctg atcag 795

```

<210> 10

<211> 824

<212> DNA

<213> Artificial Sequence

<220>

<223> SYNTHETIC MOUSE FUSION GENE

<220>

<221> sig_peptide

<222> (1)..(61)

<223> native light chain leader peptide

<220>

<221> V_region

<222> (62)..(397)

<223> LIGHT CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD22: G28-7

<220>

<221> misc_feature

<222> (398)..(445)

<223> (gly4ser)3 linker peptide

<220>

<221> V_region
<222> (445)..(818)

<223> HEAVY CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD22: G28-7

<220>

<221> misc_feature
<222> (819)..(824)

<223> BclI restriction site

<400> 10
atggagtcac attcccaggt ctttctctcc ctgctgctct gggatatctgg tacctgtggg 60
aacattatga tgacacagtc gccatcatct ctggctgtgt cagcaggaga aaaggtcact 120
atgaactgta agtccagtc aagtgttttc tacagttcaa atcagaggaa ttatttggcc 180
tggtatcagc agaaaccagg gcagtctccc aaattgctga tctactgggc atctactagg 240
gaatctgggtg tccctgatcg cttcacaggc agtggatccg ggacagactt tactcttacc 300
atcagcagtg tacatactga agacctggca gtttattact gtcacatcaatt cctctcttcg 360
tggacgttcg gtggaggcac caagctggaa atcaaaggcg gtggtgggtc ggggtgggtg 420
ggttcgggtg gcggcggatc ttctcaggtc caactgcagc agcctggggc tgaactgggtg 480
aagcctggga cttcagtga gctgtcctgc aaggcctctg gctacacctt caccaactac 540
tggatggtct ggggtgaagca gacgcctgga gaaggccttg agtggattgg agaaattatt 600
cctagcaacg gtcgactactaa atacaatgag aagttcaaga gcaaggccac actgactgca 660
gacaaatcct cccgcacagc ctacatgcaa ctcagcagcc tggcatctga ggactctgcg 720
gtctattatt gtgcaagaga gatgtccatt attactacgg tactgactcc cggtttgctt 780
actggggcca agggactctg gtcactgtct ctgcagcctg atca 824

<210> 11

<211> 266

<212> PRT

<213> Mus musculus

<220>

<221> INIT_MET

<222> (1)..(1)

<220>

<221> SIGNAL

<222> (1)..(22)

<220>

<221> DOMAIN

<222> (23)..(128)

<223> LIGHT CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD20

<220>

<221> SITE

<222> (129)..(144)

<223> ASP-(GLY3SER)-(GLY4SER)2-SER LINKER PEPTIDE

<220>

<221> DOMAIN

<222> (145)..(266)

<223> HEAVY CHAIN VARIABLE DOMAIN FOR MOUSE ANTI-HUMAN CD20

<400> 11

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1 5 10 15

Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
20 25 30

Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
35 40 45

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser

50	55	60
Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro		
65	70	75 80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile		
	85	90 95
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp		
	100	105 110
Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys		
	115	120 125
Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser		
	130	135 140
Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala		
	145	150 155 160
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr		
	165	170 175
Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile		
	180	185 190
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe		
	195	200 205
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr		
	210	215 220
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys		
	225	230 235 240
Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp		
	245	250 255
Gly Thr Gly Thr Thr Val Thr Val Ser Asp		
	260	265

<210> 12

<211> 271

<212> PRT

<213> Mus musculus

<220>

<221> SITE

<222> (1)..(271)

<223> MOUSE ANTI-HUMAN CD19 SCFV

<400> 12

Met	Glu	Thr	Asp	Thr	Leu	Leu	Leu	Trp	Val	Leu	Leu	Leu	Trp	Val	Pro
1				5					10					15	
Gly	Ser	Thr	Gly	Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Ser	Leu	Ala
			20					25					30		
Val	Ser	Leu	Gly	Gln	Arg	Ala	Thr	Ile	Ser	Cys	Lys	Ala	Ser	Gln	Ser
		35					40					45			
Val	Asp	Tyr	Asp	Gly	Asp	Ser	Tyr	Leu	Asn	Trp	Tyr	Gln	Gln	Ile	Pro
	50					55					60				
Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile	Tyr	Asp	Ala	Ser	Asn	Leu	Val	Ser
65				70						75					80
Gly	Ile	Pro	Pro	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
				85					90					95	
Leu	Asn	Ile	His	Pro	Val	Glu	Lys	Val	Asp	Ala	Ala	Thr	Tyr	His	Cys
			100					105					110		
Gln	Gln	Ser	Thr	Glu	Asp	Pro	Trp	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu
		115					120					125			
Glu	Ile	Lys	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly
	130					135						140			
Gly	Ser	Ser	Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg
145					150					155					160
Pro	Gly	Ser	Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ala	Phe
				165					170					175	
Ser	Ser	Tyr	Trp	Met	Asn	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu
			180					185					190		
Glu	Trp	Ile	Gly	Gln	Ile	Trp	Pro	Gly	Asp	Gly	Asp	Thr	Asn	Tyr	Asn
	195						200					205			
Gly	Lys	Phe	Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Glu	Ser	Ser	Ser
	210					215					220				
Thr	Ala	Tyr	Met	Gln	Leu	Ser	Ser	Leu	Ala	Ser	Glu	Asp	Ser	Ala	Val
225					230				235						240
Tyr	Phe	Cys	Ala	Arg	Arg	Glu	Thr	Thr	Thr	Val	Gly	Arg	Tyr	Tyr	Tyr
				245					250					255	
Ala	Met	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Ser	Val	Thr	Val	Ser	Ser	
			260					265					270		

<210> 13

<211> 259

<212> PRT

<213> Mus musculus

<220>

<221> SITE

<222> (1)..(259)

<223> MOUSE ANTI-HUMAN CD37 SCFV

<400> 13

```

Met Val Ser Thr Ala Gln Phe Leu Gly Leu Leu Leu Leu Trp Leu Thr
1          5          10          15

Gly Gly Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
          20          25          30

Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Thr Ser Glu Asn
          35          40          45

Val Tyr Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
50          55          60

Gln Leu Leu Val Ser Phe Ala Lys Thr Leu Ala Glu Gly Val Pro Ser
65          70          75          80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Ser
          85          90          95

Ser Leu Gln Pro Glu Asp Ser Gly Ser Tyr Phe Cys Gln His His Ser
          100          105          110

Asp Asn Pro Trp Thr Phe Gly Gly Gly Thr Glu Leu Glu Ile Lys Gly
          115          120          125

Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Ala
          130          135          140

Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly Ala Ser
145          150          155          160

Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Asn
          165          170          175

Met Asn Trp Val Lys Gln Asn Asn Gly Lys Ser Leu Glu Trp Ile Gly
          180          185          190

```

```

Asn Ile Asp Pro Tyr Tyr Gly Gly Thr Thr Tyr Asn Arg Lys Phe Lys
 195                200                205

Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met
 210                215                220

Gln Leu Lys Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
 225                230                235                240

Arg Ser Val Gly Pro Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr
 245                250                255

Val Ser Ser

```

```

<210> 14
<211> 272
<212> PRT
<213> Mus musculus

<220>
<221> SITE
<222> (1)..(272)
<223> MOUSE ANTI-HUMAN CD22 SCFV

```

```

<400> 14

Met Glu Ser His Ser Gln Val Phe Leu Ser Leu Leu Leu Trp Val Ser
 1          5          10          15

Gly Thr Cys Gly Asn Ile Met Met Thr Gln Ser Pro Ser Ser Leu Ala
 20          25          30

Val Ser Ala Gly Glu Lys Val Thr Met Asn Cys Lys Ser Ser Gln Ser
 35          40          45

Val Phe Tyr Ser Ser Asn Gln Arg Asn Tyr Leu Ala Trp Tyr Gln Gln
 50          55          60

Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg
 65          70          75          80

Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
 85          90          95

Phe Thr Leu Thr Ile Ser Ser Val His Thr Glu Asp Leu Ala Val Tyr
 100         105         110

```

```

Tyr Cys His Gln Phe Leu Ser Ser Trp Thr Phe Gly Gly Gly Thr Lys
    115                                120                125

Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly
    130                                135                140

Gly Gly Ser Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val
    145                                150                155                160

Lys Pro Gly Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr
    165                                170                175

Phe Thr Asn Tyr Trp Met Val Trp Val Lys Gln Thr Pro Gly Glu Gly
    180                                185                190

Leu Glu Trp Ile Gly Glu Ile Ile Pro Ser Asn Gly Arg Thr Lys Tyr
    195                                200                205

Asn Glu Lys Phe Lys Ser Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser
    210                                215                220

Arg Thr Ala Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala
    225                                230                235                240

Val Tyr Tyr Cys Ala Arg Glu Met Ser Ile Ile Thr Thr Val Leu Thr
    245                                250                255

Pro Gly Leu Leu Thr Gly Ala Lys Gly Leu Trp Ser Leu Ser Leu Gln
    260                                265                270

```

<210> 15

<211> 499

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(265)

<223> MOUSE ANTI-HUMAN CD20 SCFV: 2H7

<220>

<221> DOMAIN

<222> (266)..(499)

<223> HUMAN IGG1 WILD TYPE HINGE, CH2, CH3 FC

<400> 15

```

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1      5      10      15
Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
      20      25      30
Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
      35      40      45
Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser
      50      55      60
Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro
65      70      75      80
Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
      85      90      95
Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
      100      105      110
Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
      115      120      125
Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
      130      135      140
Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
145      150      155      160
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
      165      170      175
Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile
      180      185      190
Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
      195      200      205
Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
      210      215      220
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
225      230      235      240
Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
      245      250      255
Gly Thr Gly Thr Thr Val Thr Val Ser Asp Gln Glu Pro Lys Ser Cys

```

260					265					270					
Asp	Lys	Thr	His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly
	275						280					285			
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met
	290					295					300				
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His
305					310					315					320
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val
			325						330					335	
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr
			340					345					350		
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly
		355					360					365			
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile
	370					375					380				
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val
385						390					395				400
Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser
			405						410					415	
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu
			420					425					430		
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro
		435					440					445			
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val
	450					455					460				
Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met
465						470					475				480
His	Glu	Ala	Leu	His	Asn	His	Tyr	Thr	Gln	Lys	Ser	Leu	Ser	Leu	Ser
			485						490					495	
Pro	Gly	Lys													

<210> 16

<211> 499

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(265)

<223> 2H7 SCFV TARGETED TO HUMAN CD20

<220>

<221> DOMAIN

<222> (265)..(499)

<223> HINGE CYSTEINES MUTATED TO SERINES (AMINO ACIDS 272, 278, 281)
PROLINE IN CH2 MUTATED TO SERINE (AMINO ACID 290)

<400> 16

Met	Asp	Phe	Gln	Val	Gln	Ile	Phe	Ser	Phe	Leu	Leu	Ile	Ser	Ala	Ser	1	5	10	15
Val	Ile	Ile	Ala	Arg	Gly	Gln	Ile	Val	Leu	Ser	Gln	Ser	Pro	Ala	Ile	20	25	30	
Leu	Ser	Ala	Ser	Pro	Gly	Glu	Lys	Val	Thr	Met	Thr	Cys	Arg	Ala	Ser	35	40	45	
Ser	Ser	Val	Ser	Tyr	Met	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Ser	Ser	50	55	60	
Pro	Lys	Pro	Trp	Ile	Tyr	Ala	Pro	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	65	70	75	80
Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile	85	90	95	
Ser	Arg	Val	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp	100	105	110	
Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu	Lys	115	120	125	
Asp	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	130	135	140	
Gln	Ala	Tyr	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Ala	145	150	155	160

Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr		
				165					170					175			
Asn	Met	His	Trp	Val	Lys	Gln	Thr	Pro	Arg	Gln	Gly	Leu	Glu	Trp	Ile		
			180					185					190				
Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	Thr	Ser	Tyr	Asn	Gln	Lys	Phe		
		195					200					205					
Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr		
	210					215					220						
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Cys		
225					230					235					240		
Ala	Arg	Val	Val	Tyr	Tyr	Ser	Asn	Ser	Tyr	Trp	Tyr	Phe	Asp	Val	Trp		
				245					250					255			
Gly	Thr	Gly	Thr	Thr	Val	Thr	Val	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser		
			260					265					270				
Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Ala	Pro	Glu	Leu	Leu	Gly		
		275					280					285					
Gly	Ser	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met		
	290					295					300						
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His		
305					310					315					320		
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val		
				325					330				335				
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr		
			340					345					350				
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly		
		355					360					365					
Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile		
	370					375					380						
Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val		
385					390					395					400		
Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu	Leu	Thr	Lys	Asn	Gln	Val	Ser		
				405					410					415			
Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu		
			420					425					430				
Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro		
		435					440					445					
Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val		
	450					455					460						

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 465 470 475 480

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 485 490 495

Pro Gly Lys

<210> 17

<211> 499

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(265)

<223> MOUSE ANTI-HUMAN CD20 SCFV: 2H7

<220>

<221> DOMAIN

<222> (266)..(499)

<223> HINGE CYSTEINES MUTATED TO SERINES (AMINO ACIDS 272, 278, 281)
 CH2 AND CH3 DOMAINS ARE WILD TYPE IN SEQUENCE

<400> 17

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
 1 5 10 15

Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
 20 25 30

Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
 35 40 45

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser
 50 55 60

Pro	Lys	Pro	Trp	Ile	Tyr	Ala	Pro	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro	65	70	75	80
Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile	85	90	95	
Ser	Arg	Val	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp	100	105	110	
Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu	Lys	115	120	125	
Asp	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	130	135	140	
Gln	Ala	Tyr	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Ala	145	150	155	160
Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr	165	170	175	
Asn	Met	His	Trp	Val	Lys	Gln	Thr	Pro	Arg	Gln	Gly	Leu	Glu	Trp	Ile	180	185	190	
Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	Thr	Ser	Tyr	Asn	Gln	Lys	Phe	195	200	205	
Lys	Gly	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr	210	215	220	
Met	Gln	Leu	Ser	Ser	Leu	Thr	Ser	Glu	Asp	Ser	Ala	Val	Tyr	Phe	Cys	225	230	235	240
Ala	Arg	Val	Val	Tyr	Tyr	Ser	Asn	Ser	Tyr	Trp	Tyr	Phe	Asp	Val	Trp	245	250	255	
Gly	Thr	Gly	Thr	Thr	Val	Thr	Val	Ser	Asp	Gln	Glu	Pro	Lys	Ser	Ser	260	265	270	
Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser	Pro	Ala	Pro	Glu	Leu	Leu	Gly	275	280	285	
Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	290	295	300	
Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	305	310	315	320
Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	325	330	335	
His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	340	345	350	
Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	355	360	365	

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 370 375 380
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 385 390 395 400
 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 405 410 415
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 420 425 430
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 435 440 445
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 450 455 460
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 465 470 475 480
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 485 490 495

Pro Gly Lys

<210> 18

<211> 505

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(265)

<223> MOUSE ANTI-HUMAN CD20 SCFV: 2H7

<220>

<221> DOMAIN

<222> (266)..(288)

<223> WILD TYPE IGA HINGE

<220>

<221> DOMAIN

<222> (289)..(505)

<223> HUMAN IGG1 CH2 AND CH3 DOMAINS, WILD TYPE SEQUENCE

<400> 18

```

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1          5          10          15

Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
          20          25          30

Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
          35          40          45

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser
          50          55          60

Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro
65          70          75          80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
          85          90          95

Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
          100          105          110

Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
          115          120          125

Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
130          135          140

Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
145          150          155          160

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          165          170          175

Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile
          180          185          190

Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
          195          200          205

Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
210          215          220

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys

```

225		230		235		240
Ala Arg Val Val Tyr	Tyr Ser Asn Ser Tyr	Trp Tyr Phe Asp Val	Trp			
	245		250		255	
Gly Thr Gly Thr Thr	Val Thr Val Ser Asp	Gln Pro Val Pro	Ser Thr			
	260		265		270	
Pro Pro Thr Pro Ser	Pro Ser Thr Pro	Pro Thr Pro Ser	Cys			
	275		280		285	
Ala Pro Glu Leu Leu	Gly Gly Pro Ser Val	Phe Leu Phe Pro	Pro Lys			
	290		295		300	
Pro Lys Asp Thr Leu	Met Ile Ser Arg Thr	Pro Glu Val Thr	Cys Val			
	305		310		315	
Val Val Asp Val Ser	His Glu Asp Pro	Glu Val Lys Phe	Asn Trp	Tyr		
	325		330		335	
Val Asp Gly Val Glu	Val His Asn Ala	Lys Thr Lys Pro	Arg Glu	Glu		
	340		345		350	
Gln Tyr Asn Ser Thr	Tyr Arg Val Val	Ser Val Leu Thr	Val Leu	His		
	355		360		365	
Gln Asp Trp Leu Asn	Gly Lys Glu Tyr Lys	Cys Lys Val	Ser Asn	Lys		
	370		375		380	
Ala Leu Pro Ala Pro	Ile Glu Lys Thr Ile	Ser Lys Ala Lys	Gly Gln			
	385		390		395	
Pro Arg Glu Pro Gln	Val Tyr Thr Leu	Pro Pro Ser Arg	Asp Glu	Leu		
	405		410		415	
Thr Lys Asn Gln Val	Ser Leu Thr Cys	Leu Val Lys Gly	Phe Tyr	Pro		
	420		425		430	
Ser Asp Ile Ala Val	Glu Trp Glu Ser	Asn Gly Gln Pro	Glu Asn	Asn		
	435		440		445	
Tyr Lys Thr Thr Pro	Pro Val Leu Asp	Ser Asp Gly Ser	Phe Phe	Leu		
	450		455		460	
Tyr Ser Lys Leu Thr	Val Asp Lys Ser Arg	Trp Gln Gln Gly	Asn Val			
	465		470		475	
Phe Ser Cys Ser Val	Met His Glu Ala	Leu His Asn His	Tyr Thr	Gln		
	485		490		495	
Lys Ser Leu Ser Leu	Ser Pro Gly Lys					
	500		505			

<210> 19

<211> 234

<212> PRT

<213> Homo sapiens

<220>

<221> DOMAIN

<222> (1)..(234)

<223> MUTANT IGG1 HINGE (AMINO ACIDS 7, 13, 16)
WILD TYPE CH2 AND CH3 DOMAINS
ALTERNATIVE CARBOXY TERMINUS OF SCFVIG FUSION PROTEINS

<400> 19

Asp	Gln	Glu	Pro	Lys	Ser	Ser	Asp	Lys	Thr	His	Thr	Ser	Pro	Pro	Ser			
1				5					10					15				
Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	Pro	Pro			
			20					25					30					
Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	Thr	Cys			
		35					40					45						
Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro	Glu	Val	Lys	Phe	Asn	Trp			
	50					55					60							
Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	Arg	Glu			
65					70					75					80			
Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	Val	Leu			
				85					90					95				
His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	Ser	Asn			
			100					105					110					
Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	Lys	Gly			
		115					120					125						
Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	Asp	Glu			
	130					135					140							
Leu	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	Phe	Tyr			
145					150					155					160			
Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	Glu	Asn			
				165					170					175				
Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	Phe	Phe			
			180					185					190					
Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	Gly	Asn			
		195					200					205						

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 210 215 220

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 225 230

<210> 20

<211> 240

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (1)..(23)

<223> ALTERNATIVE CARBOXY TERMINUS OF SCFVIG FUSION PROTEINS

<220>

<221> DOMAIN

<222> (24)..(240)

<223> HUMAN IGG1 WILD TYPE CH2 AND CH3 FC

<400> 20

Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro
 1 5 10 15

Pro Thr Pro Ser Pro Ser Cys Ala Pro Glu Leu Leu Gly Gly Pro Ser
 20 25 30

Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
 35 40 45

Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
 50 55 60

Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
 65 70 75 80

Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
 85 90 95

Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
 100 105 110


```

Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
    115                      120                      125

Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
    130                      135                      140

Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
    145                      150                      155                      160

Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
    165                      170                      175

Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
    180                      185                      190

Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
    195                      200                      205

Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
    210                      215                      220

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
    225                      230                      235                      240

```

<210> 21

<211> 1470

<212> DNA

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID

<220>

<221> misc_feature

<222> (1)..(808)

<223> MOUSE ANTI-HUMAN CD20 SCFV

<220>

<221> misc_feature

<222> (814)..(1455)

<223> HUMAN EXTRACELLULAR DOMAIN LONG FORM, CD154

<400> 21
aagcttgccg ccattgattt tcaagtgcag attttcagct tcttgctaatt cagtgccttca 60
gtcataaattg ccagaggaca aattgtttctc tcccagttctc cagcaatcct gtctgcatct 120
ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg 180
taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct 240
tctggagtcc ctgctcgctt cagtggcagt ggggtctggga cctcttactc tctcacaatc 300
agcagagtgg aggtctgaaga tgctgccact tattactgcc agcagtggag ttttaaccca 360
cccacgttcg gtgctgggac caagctggag ctgaaagatg gcgggtggctc gggcgggtgg 420
ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctggtg 480
aggcctgggg cctcagtga gatgtcctgc aaggcttctg gctacacatt taccagttac 540
aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat 600
ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta 660
gacaaatcct ccagcacagc ctacatgcag ctacagcagc tgacatctga agactctgcg 720
gtctattttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg 780
ggcacaggga ccacggtcac cgtctctgat ccaagaagg tggacaagat agaagatgaa 840
aggaatcttc atgaagattt tgtattcatg aaaacgatac agagatgcaa cacaggagaa 900
agatccttat ccttactgaa ctgtgaggag attaaaagcc agtttgaagg ctttgtgaag 960
gatataatgt taaacaaaga ggagacgaag aaagaaaaca gctttgaaat gcaaaaagg 1020
gatcagaatc ctcaaattgc ggcacatgctc ataagtgagg ccagcagtaa aacaacatct 1080
gtgttacagt gggctgaaaa aggatactac accatgagca acaacttggg aaccctggaa 1140
aatgggaaac agctgaccgt taaaagacaa ggactctatt atatctatgc ccaagtcacc 1200
ttctgttcca atcggaagc ttcgagtcaa gctccattta tagccagcct ctgcctaaag 1260
tccccggta gattcgagag aatcttactc agagctgcaa ataccacag ttccgcaaaa 1320
ccttgcgggc aacaatocat tcaattggga ggagtatttg aattgcaacc aggtgcttcg 1380
gtgtttgtca atgtgactga tccaagccaa gtgagccatg gcactggctt cacgtccttt 1440
ggcttactca aactogagtg ataacttaga 1470

<210> 22

<211> 1290

<212> DNA

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID

<220>

<221> misc_feature

<222> (13)..(808)

<223> MOUSE ANTI-HUMAN CD20 SCFV

<220>

<221> misc_feature

<222> (814)..(1275)

<223> HUMAN EXTRACELLULAR DOMAIN, SHORT FORM, CD154

<400> 22

```

aagcttgccg ccatggattt tcaagtgcag attttcagct tcctgctaata cagtgcattca      60
gtcataattg ccagaggaca aattgttctc tcccagctctc cagcaatcct gtctgcatct      120
ccaggggaga aggtcacaat gacttgcagg gccagctcaa gtgtaagtta catgcactgg      180
taccagcaga agccaggatc ctcccccaaa ccctggattt atgccccatc caacctggct      240
tctggagtcc ctgctcgctt cagtggcagt gggctctggga cctcttactc tctcacaatc      300
agcagagtgg aggctgaaga tgctgocact tattactgcc agcagtggag ttttaaccca      360
cccacgttcg gtgctgggac caagctggag ctgaaagatg gcggtggctc gggcggtggg      420
ggatctggag gaggtgggag ctctcaggct tatctacagc agtctggggc tgagctgggt      480
aggcctgggg cctcagtga gatgtcctgc aaggcttctg gctacacatt taccagttac      540
aatatgcact gggtaaagca gacacctaga cagggcctgg aatggattgg agctatttat      600
ccaggaaatg gtgatacttc ctacaatcag aagttcaagg gcaaggccac actgactgta      660
gacaaatcct ccagcacagc ctacatgcag ctacgcagcc tgacatctga agactctgcg      720
gtctatttct gtgcaagagt ggtgtactat agtaactctt actggtactt cgatgtctgg      780

```

```

ggcacagggg ccacgggtcac cgtctctgat ccagaaaaca gctttgaaat gcaaaaaggt      840
gatcagaatc ctcaaattgc ggcacatgtc ataagtgagg ccagcagtaa aacaacatct      900
gtgttacagt gggctgaaaa aggatactac accatgagca acaacttggg aaccttgga      960
aatgggaaac agctgaccgt taaaagacaa ggactctatt atatctatgc ccaagtcacc    1020
ttctgttcca atcggaagc ttcgagtcaa gctccattta tagccagcct ctgcctaaag    1080
tcccccggtg gattcgagag aatcttactc agagctgcaa atacccacag ttccgcaaaa    1140
ccttgcgggc aacaatccat tcaattggga ggagtatttg aattgcaacc agtggttcg      1200
gtgtttgtca atgtgactga tccaagccaa gtgagccatg gcaactggctt cacgtccttt    1260
ggcttactca aactcgagtg ataattctaga                                     1290

```

<210> 23

<211> 43

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 23

gtcaagcttg ccgcatgga ttttcaagtg cagatttttc agc 43

<210> 24

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 24

gtcgtcgagc tcccacctcc tccagatcca ccaccgccg agccaccgcc acctttcagc 60

tccagcttgg tccc

74

<210> 25

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 25

gctgctgagc tctcaggctt atctacagca agtctgg

37

<210> 26

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 26

gttgtctgat cagagacggt gaccgtgggc cc

32

<210> 27

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 27

gttgtcggat ccagaaaaca gctttgaaat gcaa

34

<210> 28

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 28

gttgtttcta gattatcact cgagtttgag taagccaaag gacg

44

<210> 29

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 29

gttgtcggat ccaagaaggt tggacaagat agaag

35

<210> 30

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 30

gtctatataa gcagagctct ggc

23

<210> 31

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 31

cgaggctgat cagcgagctc tagca

25

<210> 32

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> OLIGONUCLEOTIDE

<400> 32

ccgcaatttg aggattctga tcacc

25

<210> 33

<211> 482

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(266)

<223> MOUSE ANTI-HUMAN CD20 SCFV

<220>

<221> DOMAIN

<222> (268)..(481)

<223> EXTRACELLULAR DOMAIN, LONG FORM, HUMAN CD154

<400> 33

Met	Asp	Phe	Gln	Val	Gln	Ile	Phe	Ser	Phe	Leu	Leu	Ile	Ser	Ala	Ser
1				5					10					15	

Val	Ile	Ile	Ala	Arg	Gly	Gln	Ile	Val	Leu	Ser	Gln	Ser	Pro	Ala	Ile
			20					25					30		

Leu	Ser	Ala	Ser	Pro	Gly	Glu	Lys	Val	Thr	Met	Thr	Cys	Arg	Ala	Ser
		35					40					45			

Ser	Ser	Val	Ser	Tyr	Met	His	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Ser	Ser
	50					55					60				

Pro	Lys	Pro	Trp	Ile	Tyr	Ala	Pro	Ser	Asn	Leu	Ala	Ser	Gly	Val	Pro
65					70					75					80

Ala	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Ser	Tyr	Ser	Leu	Thr	Ile
				85					90					95	

Ser	Arg	Val	Glu	Ala	Glu	Asp	Ala	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp
			100					105					110		

Ser	Phe	Asn	Pro	Pro	Thr	Phe	Gly	Ala	Gly	Thr	Lys	Leu	Glu	Leu	Lys
		115					120					125			

Asp	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser
	130					135					140				

Gln	Ala	Tyr	Leu	Gln	Gln	Ser	Gly	Ala	Glu	Leu	Val	Arg	Pro	Gly	Ala
145					150					155					160

Ser	Val	Lys	Met	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Ser	Tyr
				165					170					175	

Asn	Met	His	Trp	Val	Lys	Gln	Thr	Pro	Arg	Gln	Gly	Leu	Glu	Trp	Ile
			180					185					190		

Gly	Ala	Ile	Tyr	Pro	Gly	Asn	Gly	Asp	Thr	Ser	Tyr	Asn	Gln	Lys	Phe
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

Leu Glu

<210> 34

<211> 422

<212> PRT

<213> Artificial Sequence

<220>

<223> MOUSE-HUMAN HYBRID FUSION PROTEIN

<220>

<221> SITE

<222> (1)..(266)

<223> MOUSE ANTI-HUMAN SCFV

<220>

<221>

DOMAIN

<222> (268)..(421)

<223> EXTRACELLULAR DOMAIN, SHORT FORM, HUMAN CD154

<400> 34

Met Asp Phe Gln Val Gln Ile Phe Ser Phe Leu Leu Ile Ser Ala Ser
1 5 10 15

Val Ile Ile Ala Arg Gly Gln Ile Val Leu Ser Gln Ser Pro Ala Ile
20 25 30

Leu Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
35 40 45

Ser Ser Val Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Ser Ser
50 55 60

Pro Lys Pro Trp Ile Tyr Ala Pro Ser Asn Leu Ala Ser Gly Val Pro
65 70 75 80

Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95

Ser Arg Val Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
100 105 110

Ser Phe Asn Pro Pro Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 115 120 125
 Asp Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser
 130 135 140
 Gln Ala Tyr Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ala
 145 150 155 160
 Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
 165 170 175
 Asn Met His Trp Val Lys Gln Thr Pro Arg Gln Gly Leu Glu Trp Ile
 180 185 190
 Gly Ala Ile Tyr Pro Gly Asn Gly Asp Thr Ser Tyr Asn Gln Lys Phe
 195 200 205
 Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 210 215 220
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 225 230 235 240
 Ala Arg Val Val Tyr Tyr Ser Asn Ser Tyr Trp Tyr Phe Asp Val Trp
 245 250 255
 Gly Thr Gly Thr Thr Val Thr Val Ser Asp Pro Glu Asn Ser Phe Glu
 260 265 270
 Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
 275 280 285
 Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
 290 295 300
 Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
 305 310 315 320
 Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
 325 330 335
 Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
 340 345 350
 Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
 355 360 365
 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
 370 375 380
 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
 385 390 395 400
 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
 405 410 415

Gly Leu Leu Lys Leu Glu
420

<210> 35

<211> 63

<212> DNA

<213> Homo sapiens

<220>

<221> N region

<222> (1)..(63)

<223> PORTION OF HUMAN IGA HINGE DOMAIN CONTAINING ONLY 1 CYSTEINE

<400> 35

ccagttccct caactccacc taccccatct cctcaactc cacctacccc atctccctca 60

tgc 63

<210> 36

<211> 21

<212> PRT

<213> Homo sapiens

<400> 36

Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro Pro Thr
1 5 10 15

Pro Ser Pro Ser Cys
20

<210> 37

<211> 763

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)..(6)

<223> BCLI SITE FOR FUSION TO AMIN TERMINAL SCFVS

<220>

<221> N_region

<222> (8)..(752)

<223> WILD TYPE IGA HINGE, CH2, CH3 DOMAINS
TRUNCATED TO REMOVE SECRETORY COMPONENT ATTACHMENT

<400> 37
tgatcagcca gttccctcaa ctccacctac cccatctccc tcaactccac ctaccccatc 60
tcctcatgc tgccaccccc gactgtcact gcaccgaccg gccctcgagg acctgctctt 120
aggttcagaa gcgatcctca cgtgcacact gaccggcctg agagatgcct caggtgtcac 180
cttcacctgg acgccctcaa gtgggaagag cgctgttcaa ggaccacctg accgtgacct 240
ctgtggctgc tacagcgtgt ccagtgtcct gccgggctgt gccgagccat ggaaccatgg 300
gaagaccttc acttgactg ctgcctaccc cgagtccaag accccgctaa ccgccaccct 360
ctcaaaatcc ggaaacacat tccggcccga ggtccacctg ctgccgccgc cgtcggagga 420
gctggccctg aacgagctgg tgacgctgac gtgcctggca cgtggcttca gcccgaagga 480
tgtgtgtggt cgctggctgc aggggtcaca ggagctgccc cgcgagaagt acctgacttg 540
ggcatcccgg caggagccca gccagggcac caccaccttc gctgtgacca gcatactgcg 600
cgtggcagcc gaggactgga agaaggggga caccttctcc tgcattgttg gccacgaggc 660
cctgccgtg gccttcacac agaagacat cgaccgcttg gcgggtaaac ccacccatgt 720
caatgtgtct gttgtcatgg cggaggtgga ctgataatct aga 763

<210> 38

<211> 250

<212> PRT

<213> Homo sapiens

<220>

<221> DOMAIN

<222> (3)..(250)

<223> TRUNCATED FORM, REMOVAL OF LAST THREE AMINO ACIDS THAT MEDIATE ATTACHMENT TO SECRETORY COMPONENT

<400> 38

Asp Gln Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr Pro
1 5 10 15

Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His Arg
20 25 30

Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Ile Leu Thr Cys
35 40 45

Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe Thr Trp Thr
50 55 60

Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro Asp Arg Asp Leu
65 70 75 80

Cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys Ala Glu Pro
85 90 95

Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr Pro Glu Ser
100 105 110

Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr Phe Arg
115 120 125

Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn
130 135 140

Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp
145 150 155 160

Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro Arg Glu Lys
165 170 175

Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly Thr Thr Thr
180 185 190

Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp Lys Lys
195 200 205

Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu Ala
210 215 220

Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro Thr His Val
225 230 235 240

Asn Val Ser Val Val Met Ala Glu Val Asp
245 250